8:00 am Registration & Breakfast

8:50 am Chair’s Opening Remarks

• Gail Lewis Senior Principal Scientist, Genentech

Utilizing Late Stage Development Data for Improved Targeting & Combination Partner Selection

9:00 am HER2-low: The shifting Paradigm and Evolving HER2 Classification in Breast Cancer

• Simone Sredni Director of Medical Diagnostics, AstraZeneca

9:30 am Identifying Scientifically Rational Combination Partners for Improving Efficacy

• Jay Mettetal Senior Director - Oncology Bioscience, AstraZeneca

10:00 am Morning Break & Networking

Hitting Moving Targets – Approaches to Treating HER2+ Metastases

11:00 am Learnings From a Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of A Novel Therapeutic in Locally Advanced/Metastatic HER2- Expressing Solid Tumors

• Sadhna Shankar, MD, MPH Vice President of Early Phase, Clinical Research, Oncology, Eisai

11:30 am Panel Discussion: Discuss the Strengths of Immunological Approaches to Tumor Killing in HER2+ Approaches

• David Ferry Senior Vice President of Clinical Development, Dragonfly Therapeutics
• Andy Bader Chief Scientific Officer, Trimuvira Immunologics

12:00 pm Lunch Break

1:00 pm Novel Approach to Treatment of HER2 Gastric Cancers – Recent Data Release & the Perspective for Improving the Patient Experience

• Andy Bader Chief Scientific Officer, Trimuvira Immunologics

2:00 pm Achieving Strong Antitumor Responses with Molecularly Targeted Radiation

• Jennifer Wheler President, Navigate BioConsulting

3:00 pm Panel Discussion: Therapeutic & Diagnostic Potential of a Burgeoning Branch of Biotech

• Guido Würth Global Head of Programs, Affibody AB
• Jennifer Wheler President, Navigate BioConsulting
• Thom Tulip Chief Business Officer, Radiopharm Theranostics

3:45 pm Chair’s Closing Remarks

• Gail Lewis Senior Principal Scientist, Genentech

4:00 pm End of Conference